We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Participants given the lower dose of 25 mcg had levels of antibodies equivalent to those seen in convalescent plasma from COVID-19 survivors. Read More
Moderna has reported positive early results from a phase 1 trial of its COVID-19 vaccine candidate, mRNA-1273, with all participants producing antibodies to the virus within 15 days of a single dose. It hopes to launch a phase 3 trial in July in an extremely expedited time frame. Read More
The National Institutes of Health (NIH)’s public-private partnership to work on COVID-19 has decided on six existing treatments to evaluate in trials later this month, and said it looks to have vaccine candidates ready for trials by the start of July. Read More
Trials of pulmonary/respiratory, neurology and rheumatology therapies have the lowest representation of African Americans and other ethnic minorities, while Hispanic/Latinx populations are the most underserved in pivotal oncology trials. Read More
A new study in France has found that hydroxychloroquine provides no benefit for COVID-19 patients, adding to the growing evidence that the anti-malaria drug has little value as a coronavirus treatment. Read More
President Trump on Friday outlined a strikingly ambitious plan to have a COVID-19 vaccine approved by the FDA and starting to be deployed by year’s end. Read More
Previous research in laboratory settings and animal studies suggest that interferon-lambda may help control viruses that cause respiratory illnesses, such as influenza and SARS. Read More
As a growing number of studies raise alarms about using hydroxychloroquine to treat COVID-19, the National Institutes of Health (NIH) is starting a large clinical trial to evaluate the drug in combination with the antibiotic azithromycin. Read More